26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse.
about
Arrhythmogenic right ventricular cardiomyopathy (ARVC): case report and review of literature.Risk of competitive sport in young athletes with heart disease.Hypertrophic cardiomyopathy as a cause of sudden death.Return to Sport for Skeletally Immature Athletes After ACL Reconstruction: Preventing a Second Injury Using a Quality of Movement Assessment and Quantitative Measures to Address Modifiable Risk Factors.Management of hypertrophic cardiomyopathy.A Review of Sudden Cardiac Death in Young Athletes and Strategies for Preparticipation Cardiovascular ScreeningCanadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesNational Athletic Trainers' Association position statement: Preparticipation physical examinations and disqualifying conditions.Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the LiteraturePeriodontal implications: medically compromised patients.Health considerations for children with congenital heart disease in school. Part 2.Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy.
P2860
Q27317681-EAA9ABD7-73BF-4EAD-825C-A810F4CB68BBQ33149034-3FA51857-7B7D-42F8-9DB1-89E72C98618BQ33157576-F82056B0-3805-4902-B7B1-AC903CB2AA0FQ33589878-874925F4-C198-4992-93BA-AEBF6800D03EQ34647057-AA0B4FB1-46DD-4748-AAA7-230959115A08Q35008923-4DDA0A2E-08A9-43A9-A876-3AC69342B100Q37061992-BF1423F5-97C4-4286-A778-8ED3930330D4Q37566262-358B7807-BA01-4FC5-B71C-5081C4D81263Q38008386-606F56D0-01C5-4CE0-BD37-F988346916F4Q41444849-03AE979A-9294-46A6-BE78-EE2104C63A68Q43487414-8EB033E4-EE83-45F8-8A7B-38B6B57D694CQ46711295-0EF39E0F-79F4-44BB-8FA5-C55EE4C1E0F1
P2860
26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
26th Bethesda conference: reco ...... ses and mitral valve prolapse.
@en
type
label
26th Bethesda conference: reco ...... ses and mitral valve prolapse.
@en
prefLabel
26th Bethesda conference: reco ...... ses and mitral valve prolapse.
@en
P2093
P1476
26th Bethesda conference: reco ...... ses and mitral valve prolapse.
@en
P2093
P304
P356
10.1016/0735-1097(94)90844-3
P407
P577
1994-10-01T00:00:00Z